{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:28:31Z","timestamp":1791919711048,"version":"4.3.4"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"DOI":"10.1186\/s13058-025-01989-9","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T05:13:06Z","timestamp":1742015586000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Pathologic response rates in HER2-low versus HER2-zero early breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-8135","authenticated-orcid":false,"given":"Francisco Cezar Aquino","family":"de Moraes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0069-5648","authenticated-orcid":false,"given":"Caio Henrique Duarte","family":"de Castro Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3825-5212","authenticated-orcid":false,"given":"Felipe Dirc\u00eau Dantas Leite","family":"Pess\u00f4a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Ramos","family":"Chaves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Paula Borges","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Di Felipe \u00c1vila Alcantara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margareth Maria Braun Guimar\u00e3es","family":"Imbiriba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7748-8399","authenticated-orcid":false,"given":"Maria Cristina Figueroa","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4872-234X","authenticated-orcid":false,"given":"Rommel Mario Rodr\u00edguez","family":"Burbano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"1989_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"1989_CR2","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1126\/science.3798106","volume":"235","author":"DJ Slamon","year":"1987","unstructured":"Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene. Science. 1987;235:177\u201382.","journal-title":"Science"},{"key":"1989_CR3","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/bjc.1991.101","volume":"63","author":"C Lovekin","year":"1991","unstructured":"Lovekin C, Ellis IO, Locker A, Robertson JF, Bell J, Nicholson R, et al. c-erbB-2 oncoprotein expression in primary and advanced breast cancer. Br J Cancer. 1991;63:439\u201343.","journal-title":"Br J Cancer"},{"key":"1989_CR4","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","volume":"89","author":"P Carter","year":"1992","unstructured":"Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, et al. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 1992;89:4285\u20139.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1989_CR5","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","volume":"357","author":"CA Hudis","year":"2007","unstructured":"Hudis CA. Trastuzumab\u2013mechanism of action and use in clinical practice. N Engl J Med. 2007;357:39\u201351.","journal-title":"N Engl J Med"},{"key":"1989_CR6","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: american society of clinical oncology\/college of american pathologists clinical practice guideline focused update. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:2105\u201322.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1989_CR7","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1016\/j.annonc.2023.05.008","volume":"34","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Viale G, Press MF, Hu X, Penault-Llorca F, Bardia A, et al. ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer. Ann Oncol Off J Eur Soc Med Oncol. 2023;34:645\u201359.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"1989_CR8","doi-asserted-by":"publisher","first-page":"1951","DOI":"10.1200\/JCO.19.02488","volume":"38","author":"P Tarantino","year":"2020","unstructured":"Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E, et al. HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38:1951\u201362.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1989_CR9","first-page":"1177","volume":"8","author":"P Tarantino","year":"2022","unstructured":"Tarantino P, Jin Q, Tayob N, Jeselsohn RM, Schnitt SJ, Vincuilla J, et al. Prognostic and biologic significance of ERBB2-low expression in early-stage breast cancer. JAMA Oncol. 2022;8:1177\u201383.","journal-title":"JAMA Oncol"},{"key":"1989_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000346837","volume":"8","author":"N Harbeck","year":"2013","unstructured":"Harbeck N, Beckmann MW, Rody A, Schneeweiss A, M\u00fcller V, Fehm T, et al. HER2 dimerization inhibitor pertuzumab-mode of action and clinical data in breast cancer. Breast Care Basel Switz. 2013;8:49\u201355.","journal-title":"Breast Care Basel Switz"},{"key":"1989_CR11","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","volume":"5","author":"MC Franklin","year":"2004","unstructured":"Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell. 2004;5:317\u201328.","journal-title":"Cancer Cell"},{"key":"1989_CR12","doi-asserted-by":"publisher","first-page":"111682","DOI":"10.1016\/j.ejmech.2019.111682","volume":"183","author":"Z Xu","year":"2019","unstructured":"Xu Z, Guo D, Jiang Z, Tong R, Jiang P, Bai L, et al. Novel HER2-targeting antibody-drug conjugates of trastuzumab beyond T-DM1 in breast cancer: trastuzumab deruxtecan(DS-8201a) and (Vic-)trastuzumab duocarmazine (SYD985). Eur J Med Chem. 2019;183:111682.","journal-title":"Eur J Med Chem"},{"key":"1989_CR13","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago JZ, Modi S, Chandarlapaty S. Unlocking the potential of antibody\u2013drug conjugates for cancer therapy. Nat Rev Clin Oncol. 2021;18:327\u201344.","journal-title":"Nat Rev Clin Oncol"},{"key":"1989_CR14","doi-asserted-by":"publisher","first-page":"6447","DOI":"10.3390\/curroncol30070474","volume":"30","author":"T Xiao","year":"2023","unstructured":"Xiao T, Ali S, Mata DGMM, Lohmann AE, Blanchette PS. Antibody-drug conjugates in breast cancer: ascent to destiny and beyond-a 2023 review. Curr Oncol Tor Ont. 2023;30:6447\u201361.","journal-title":"Curr Oncol Tor Ont"},{"key":"1989_CR15","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1007\/s11864-023-01068-1","volume":"24","author":"C Corti","year":"2023","unstructured":"Corti C, Giugliano F, Nicol\u00f2 E, Tarantino P, Criscitiello C, Curigliano G. HER2-low breast cancer: a new subtype? Curr Treat Options Oncol. 2023;24:468\u201378.","journal-title":"Curr Treat Options Oncol"},{"key":"1989_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/ajcp\/aqab117","volume":"157","author":"H Zhang","year":"2022","unstructured":"Zhang H, Katerji H, Turner BM, Hicks DG. HER2-low breast cancers. Am J Clin Pathol. 2022;157:328\u201336.","journal-title":"Am J Clin Pathol"},{"key":"1989_CR17","doi-asserted-by":"publisher","first-page":"12382","DOI":"10.1038\/s41598-023-39372-3","volume":"13","author":"M Yang","year":"2023","unstructured":"Yang M, Sun J, Liu L, Kong X, Lin D, Zhou H, et al. Clinicopathological characteristics of HER2-low breast cancer: a retrospective study. Sci Rep. 2023;13:12382.","journal-title":"Sci Rep"},{"key":"1989_CR18","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s12282-023-01490-1","volume":"30","author":"SM Ilie","year":"2023","unstructured":"Ilie SM, Briot N, Constantin G, Roussot N, Ilie A, Bergeron A, et al. Pathologic complete response and survival in HER2-low and HER2-zero early breast cancer treated with neoadjuvant chemotherapy. Breast Cancer. 2023;30:997\u20131007.","journal-title":"Breast Cancer"},{"key":"1989_CR19","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/S1470-2045(21)00301-6","volume":"22","author":"C Denkert","year":"2021","unstructured":"Denkert C, Seither F, Schneeweiss A, Link T, Blohmer J-U, Just M, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22:1151\u201361.","journal-title":"Lancet Oncol"},{"key":"1989_CR20","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.","journal-title":"BMJ"},{"key":"1989_CR21","unstructured":"Cochrane handbook for systematic reviews of interventions [Internet]. [cited 2024 Jul 25]. Available from: https:\/\/training.cochrane.org\/handbook"},{"key":"1989_CR22","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1200\/JCO.20.03613","volume":"39","author":"SM Tolaney","year":"2021","unstructured":"Tolaney SM, Garrett-Mayer E, White J, Blinder VS, Foster JC, Amiri-Kordestani L, et al. Updated standardized definitions for efficacy end points (STEEP) in adjuvant breast cancer clinical trials: STEEP version 2.0. J Clin Oncol. 2021;39:2720\u201331.","journal-title":"J Clin Oncol"},{"key":"1989_CR23","doi-asserted-by":"publisher","first-page":"4433","DOI":"10.1200\/JCO.23.00435","volume":"41","author":"JK Litton","year":"2023","unstructured":"Litton JK, Regan MM, Pusztai L, Rugo HS, Tolaney SM, Garrett-Mayer E, et al. Standardized definitions for efficacy end points in neoadjuvant breast cancer clinical trials: NeoSTEEP. J Clin Oncol. 2023;41:4433\u201342.","journal-title":"J Clin Oncol"},{"key":"1989_CR24","unstructured":"Wells G, Shea B, O\u2019Connell D, Peterson je, Welch V, Losos M, et al. The Newcastle\u2013Ottawa scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. 2000."},{"key":"1989_CR25","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1146\/annurev-publhealth-051920-114020","volume":"43","author":"MB Mathur","year":"2022","unstructured":"Mathur MB, VanderWeele TJ. Methods to address confounding and other biases in meta-analyses: review and recommendations. Annu Rev Public Health. 2022;43:19\u201335.","journal-title":"Annu Rev Public Health"},{"key":"1989_CR26","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.jspi.2009.09.017","volume":"140","author":"D Jackson","year":"2010","unstructured":"Jackson D, Bowden J, Baker R. How does the DerSimonian and Laird procedure for random effects meta-analysis compare with its more efficient but harder to compute counterparts? J Stat Plan Inference. 2010;140:961\u201370.","journal-title":"J Stat Plan Inference"},{"key":"1989_CR27","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s10869-022-09840-0","volume":"38","author":"S Kepes","year":"2023","unstructured":"Kepes S, Wang W, Cortina JM. Assessing publication bias: a 7-step user\u2019s guide with best-practice recommendations. J Bus Psychol. 2023;38:957\u201382.","journal-title":"J Bus Psychol"},{"key":"1989_CR28","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s10549-021-06365-7","volume":"190","author":"LL de Moura","year":"2021","unstructured":"de Moura LL, Cesca MG, Tavares MC, Santana DM, Saldanha EF, Guimar\u00e3es PT, et al. HER2-low status and response to neoadjuvant chemotherapy in HER2 negative early breast cancer. Breast Cancer Res Treat. 2021;190:155\u201363.","journal-title":"Breast Cancer Res Treat"},{"issue":"176","key":"1989_CR29","first-page":"30","volume":"2022","author":"S Kang","year":"1990","unstructured":"Kang S, Lee SH, Lee HJ, Jeong H, Jeong JH, Kim JE, et al. Pathological complete response, long-term outcomes, and recurrence patterns in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy. Eur J Cancer. 1990;2022(176):30\u201340.","journal-title":"Eur J Cancer"},{"key":"1989_CR30","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1007\/s12282-022-01431-4","volume":"30","author":"J-J Li","year":"2023","unstructured":"Li J-J, Yu Y, Ge J. HER2-low-positive and response to NACT and prognosis in HER2-negative non-metastatic BC. Breast Cancer Tokyo Jpn. 2023;30:364\u201378.","journal-title":"Breast Cancer Tokyo Jpn"},{"key":"1989_CR31","doi-asserted-by":"publisher","first-page":"152125","DOI":"10.1016\/j.anndiagpath.2023.152125","volume":"64","author":"W Qiao","year":"2023","unstructured":"Qiao W, Guo W, Liu Q, Guo X, Deng M. Pathological complete response and prognosis after neoadjuvant chemotherapy in patients with HER2-low breast cancer. Ann Diagn Pathol. 2023;64:152125\u2013152125.","journal-title":"Ann Diagn Pathol"},{"key":"1989_CR32","doi-asserted-by":"publisher","first-page":"8026","DOI":"10.1245\/s10434-022-12369-4","volume":"29","author":"Y Shao","year":"2022","unstructured":"Shao Y, Yu Y, Luo Z, Guan H, Zhu F, He Y, et al. Clinical, pathological complete response, and prognosis characteristics of HER2-low breast cancer in the neoadjuvant chemotherapy setting: a retrospective analysis. Ann Surg Oncol. 2022;29:8026\u201334.","journal-title":"Ann Surg Oncol"},{"key":"1989_CR33","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1093\/jjco\/hyad009","volume":"53","author":"W Xu","year":"2023","unstructured":"Xu W, Jiang Y, Xu L, Li C, Wang J, Liu Z, et al. HER2-low status may predict poor neoadjuvant chemotherapy response in HR-negative breast cancer: a real-world multicenter study. Jpn J Clin Oncol. 2023;53:463\u201371.","journal-title":"Jpn J Clin Oncol"},{"key":"1989_CR34","doi-asserted-by":"crossref","unstructured":"Garufi G, Carbognin L, Mastrantoni L, Maliziola N, Monte ED, Arcuri G, et al. 138P activity and efficacy of neoadjuvant chemotherapy (NACT) in luminal-HER2-negative early breast cancer (EBC) according to HER2 score (low vs score 0): A retrospective study. ESMO Open [Internet]. 2023 [cited 2024 Feb 13];8. Available from: https:\/\/www.esmoopen.com\/article\/S2059-7029(23)00703-2\/fulltext","DOI":"10.1016\/j.esmoop.2023.101477"},{"key":"1989_CR35","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.3390\/cancers15194678","volume":"15","author":"P P\u00f6schke","year":"2023","unstructured":"P\u00f6schke P, Fasching PA, Adler W, R\u00fcbner M, Beckmann MW, Hack CC, et al. Clinical characteristics and prognosis of HER2-0 and HER2-low-positive breast cancer patients: real-world data from patients treated with neoadjuvant chemotherapy. Cancers. 2023;15:4678.","journal-title":"Cancers"},{"key":"1989_CR36","doi-asserted-by":"publisher","first-page":"5653","DOI":"10.1245\/s10434-023-13311-y","volume":"30","author":"L Yang","year":"2023","unstructured":"Yang L, Liu Y, Han D, Fu S, Guo S, Bao L, et al. Clinical genetic features and neoadjuvant chemotherapy response in HER2-low breast cancers: a retrospective. Multicent Cohort Study Ann Surg Oncol. 2023;30:5653\u201362.","journal-title":"Multicent Cohort Study Ann Surg Oncol"},{"key":"1989_CR37","doi-asserted-by":"publisher","first-page":"117955492312024","DOI":"10.1177\/11795549231202463","volume":"17","author":"L Dai","year":"2023","unstructured":"Dai L, Huang Q, Guo R, Zhu K, Tang Y, Chen D, et al. Clinicopathologic features and prognosis of female early breast cancer with HER2 low expression: a propensity score matched analysis. Clin Med Insights Oncol. 2023;17:11795549231202464.","journal-title":"Clin Med Insights Oncol"},{"key":"1989_CR38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12916-022-02346-9","volume":"20","author":"G Zhang","year":"2022","unstructured":"Zhang G, Ren C, Li C, Wang Y, Chen B, Wen L, et al. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. BMC Med. 2022;20:142.","journal-title":"BMC Med"},{"key":"1989_CR39","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.humpath.2023.11.003","volume":"142","author":"C Karakas","year":"2023","unstructured":"Karakas C, Tyburski H, Turner BM, Weiss A, Akkipeddi SMK, Dhakal A, et al. HER2 categorical changes after neoadjuvant chemotherapy: a study of 192 matched breast cancers with the inclusion of HER2-low category. Hum Pathol. 2023;142:34\u201341.","journal-title":"Hum Pathol"},{"key":"1989_CR40","first-page":"oyad275","volume":"29","author":"Y Ma","year":"2023","unstructured":"Ma Y, Jiao D, Zhang J, Lv M, Chen X, Liu Z. HER2-low status was associated with better breast cancer-specific survival in early-stage triple-negative breast cancer. Oncologist. 2023;29:oyad275.","journal-title":"Oncologist"},{"key":"1989_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41523-022-00434-w","volume":"8","author":"F Miglietta","year":"2022","unstructured":"Miglietta F, Griguolo G, Bottosso M, Giarratano T, Lo Mele M, Fassan M, et al. HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment. Npj Breast Cancer. 2022;8:1\u20137.","journal-title":"Npj Breast Cancer"},{"key":"1989_CR42","first-page":"e22330","volume":"14","author":"FR Alves","year":"2022","unstructured":"Alves FR, Gil L, Vasconcelos de Matos L, Baleiras A, Vasques C, Neves MT, et al. Impact of human epidermal growth factor receptor 2 (HER2) low status in response to neoadjuvant chemotherapy in early breast cancer. Cureus. 2022;14:e22330.","journal-title":"Cureus."},{"key":"1989_CR43","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/s41416-023-02403-x","volume":"129","author":"S Zhu","year":"2023","unstructured":"Zhu S, Lu Y, Fei X, Shen K, Chen X. Pathological complete response, category change, and prognostic significance of HER2-low breast cancer receiving neoadjuvant treatment: a multicenter analysis of 2489 cases. Br J Cancer. 2023;129:1274\u201383.","journal-title":"Br J Cancer"},{"key":"1989_CR44","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s12094-022-03062-9","volume":"25","author":"W Wang","year":"2023","unstructured":"Wang W, Zhu T, Chen H, Yao Y. The impact of HER2-low status on response to neoadjuvant chemotherapy in clinically HER2-negative breast cancer. Clin Transl Oncol. 2023;25:1673\u201381.","journal-title":"Clin Transl Oncol"},{"key":"1989_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1016295\/full","author":"A Toss","year":"2022","unstructured":"Toss A, Venturelli M, Civallero M, Piombino C, Domati F, Barbolini M, et al. Predictive factors for relapse in triple-negative breast cancer patients without pathological complete response after neoadjuvant chemotherapy. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.1016295\/full.","journal-title":"Front Oncol"},{"key":"1989_CR46","doi-asserted-by":"publisher","first-page":"102666","DOI":"10.1016\/j.nano.2023.102666","volume":"49","author":"W Shi","year":"2023","unstructured":"Shi W, Wan X, Wang Y, He J, Huang X, Xu Y, et al. Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: a promising treatment option for HER2-low-positive breast cancer. Nanomed Nanotechnol Biol Med. 2023;49:102666.","journal-title":"Nanomed Nanotechnol Biol Med"},{"key":"1989_CR47","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ejca.2022.09.017","volume":"176","author":"A de Nonneville","year":"2022","unstructured":"de Nonneville A, Houvenaeghel G, Cohen M, Sabiani L, Bannier M, Viret F, et al. Pathological complete response rate and disease-free survival after neoadjuvant chemotherapy in patients with HER2-low and HER2-0 breast cancers. Eur J Cancer. 2022;176:181\u20138.","journal-title":"Eur J Cancer"},{"key":"1989_CR48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s10549-023-07171-z","volume":"204","author":"H Li","year":"2024","unstructured":"Li H, Plichta JK, Li K, Jin Y, Thomas SM, Ma F, et al. Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis. Breast Cancer Res Treat. 2024;204:89\u2013105.","journal-title":"Breast Cancer Res Treat"},{"key":"1989_CR49","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3390\/cancers14102509","volume":"14","author":"C Domergue","year":"2022","unstructured":"Domergue C, Martin E, Lemari\u00e9 C, J\u00e9z\u00e9quel P, Frenel J-S, Augereau P, et al. Impact of HER2 status on pathological response after neoadjuvant chemotherapy in early triple-negative breast cancer. Cancers. 2022;14:2509.","journal-title":"Cancers"},{"key":"1989_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2022.996434","author":"S Di Cosimo","year":"2022","unstructured":"Di Cosimo S, La Rocca E, Ljevar S, De Santis MC, Bini M, Cappelletti V, et al. Moving HER2-low breast cancer predictive and prognostic data from clinical trials into the real world. Front Mol Biosci. 2022. https:\/\/doi.org\/10.3389\/fmolb.2022.996434.","journal-title":"Front Mol Biosci"},{"key":"1989_CR51","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.3390\/cancers15041157","volume":"15","author":"S Zhang","year":"2023","unstructured":"Zhang S, Liu Y, Liu X, Liu Y, Zhang J. Prognoses of patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer receiving neoadjuvant chemotherapy before surgery: a retrospective analysis. Cancers. 2023;15:1157.","journal-title":"Cancers"},{"key":"1989_CR52","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03318-y","author":"X Yi","year":"2023","unstructured":"Yi X, Hu S, Ma M, Huang D, Zhang Y. Effect of HER2-low expression on neoadjuvant efficacy in operable breast cancer. Clin Transl Oncol. 2023. https:\/\/doi.org\/10.1007\/s12094-023-03318-y.","journal-title":"Clin Transl Oncol"},{"key":"1989_CR53","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1159\/000533787","volume":"102","author":"S Zhang","year":"2023","unstructured":"Zhang S, Yu X, Xiu Y, Qiao K, Jiang C, Huang Y. Clinicopathological characteristics of breast cancer patients with HER-2 low expression receiving neoadjuvant therapy. Oncology. 2023;102:122\u201330.","journal-title":"Oncology"},{"key":"1989_CR54","doi-asserted-by":"publisher","first-page":"PS4-22","DOI":"10.1158\/1538-7445.SABCS20-PS4-22","volume":"81","author":"T Reinert","year":"2021","unstructured":"Reinert T, Sartori GP, Souza AA, Pellegrini R, Rosa ML, Rossatto N, et al. Abstract PS4\u201322: prevalence of HER2-low and HER2-zero subgroups and correlation with response to neoadjuvant chemotherapy (NACT) in patients with HER2-negative breast cancer. Cancer Res. 2021;81:PS4-22.","journal-title":"Cancer Res"},{"key":"1989_CR55","first-page":"3571","volume":"13","author":"Y Li","year":"2023","unstructured":"Li Y, Maimaitiaili A, Qu F, Li G, Shi B, Wang Y, et al. Effect of HER2-low-positive status on neoadjuvant chemotherapy and survival outcome of breast cancer: a 10-year dual-center retrospective study. Am J Cancer Res. 2023;13:3571\u201381.","journal-title":"Am J Cancer Res"},{"key":"1989_CR56","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/BCTT.S407896","volume":"15","author":"Y Jin","year":"2023","unstructured":"Jin Y, Lan A, Dai Y, Jiang L, Liu S. Comparison of the pCR rate and DFS among breast cancer patients with different hormone receptor and HER2 statuses. Breast Cancer Targets Ther. 2023;15:327\u201335.","journal-title":"Breast Cancer Targets Ther"},{"key":"1989_CR57","doi-asserted-by":"publisher","first-page":"316","DOI":"10.21873\/cdp.10111","volume":"2","author":"G Douganiotis","year":"2022","unstructured":"Douganiotis G, Kontovinis L, Markopoulou E, Ainali A, Zarampoukas T, Natsiopoulos I, et al. Prognostic significance of low HER2 expression in patients with early hormone receptor positive breast cancer. Cancer Diagn Progn. 2022;2:316\u201323.","journal-title":"Cancer Diagn Progn"},{"key":"1989_CR58","doi-asserted-by":"publisher","first-page":"S64","DOI":"10.1016\/S0960-9776(23)00243-6","volume":"68","author":"O Djurmez","year":"2023","unstructured":"Djurmez O, Calamac M, Stanic N, Dimitrijevic M, Vukosavljevic J, Serovic K, et al. Pathological complete response after neoadjuvant chemotherapy in patients with HER2 low and HER2 0 early breast cancer (eBC) experience from Institute for Oncology and Radiology of Serbia (IORS). Breast. 2023;68:S64\u2013S64.","journal-title":"Breast"},{"issue":"201","key":"1989_CR59","first-page":"113920","volume":"2024","author":"P Tarantino","year":"1990","unstructured":"Tarantino P, Ajari O, Graham N, Vincuilla J, Parker T, Hughes ME, et al. Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer. Eur J Cancer Oxf Engl. 1990;2024(201):113920.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"1989_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.999716\/full","author":"L Tang","year":"2022","unstructured":"Tang L, Li Z, Shu X, Xu Y, Liu S. Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: a real-world retrospective study. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.999716\/full.","journal-title":"Front Oncol"},{"key":"1989_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.breast.2022.12.006","volume":"67","author":"S Zhou","year":"2023","unstructured":"Zhou S, Liu T, Kuang X, Zhen T, Shi H, Lin Y, et al. Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer. Breast Edinb Scotl. 2023;67:1\u20137.","journal-title":"Breast Edinb Scotl"},{"key":"1989_CR62","doi-asserted-by":"publisher","first-page":"103666","DOI":"10.1016\/j.breast.2023.103666","volume":"73","author":"Y Shao","year":"2024","unstructured":"Shao Y, Guan H, Luo Z, Yu Y, He Y, Chen Q, et al. Clinicopathological characteristics and value of HER2-low expression evolution in breast cancer receiving neoadjuvant chemotherapy. Breast Edinb Scotl. 2024;73:103666.","journal-title":"Breast Edinb Scotl"},{"key":"1989_CR63","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1097\/CEJ.0000000000000813","volume":"32","author":"D Tuluhong","year":"2023","unstructured":"Tuluhong D, Li X, Gao H, Zhu Y, Li Q, Wang S. Molecular characteristics and prognosis of breast cancer patients with different level of HER2 positivity after adjuvant and neoadjuvant chemotherapy. Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP. 2023;32:377\u201387.","journal-title":"Eur J Cancer Prev Off J Eur Cancer Prev Organ ECP"},{"key":"1989_CR64","doi-asserted-by":"publisher","first-page":"e13148","DOI":"10.1200\/JCO.2024.42.16_suppl.e13148","volume":"42","author":"M Abou Khalil","year":"2024","unstructured":"Abou Khalil M, Habibian L, Martin C, Semaan K, Khaddage A, El Kassis N, et al. Landscape of HER2-low breast cancer: Insights from a six-year study on incidence and clinicopathological characteristics. J Clin Oncol. 2024;42:e13148\u2013e13148.","journal-title":"J Clin Oncol"},{"key":"1989_CR65","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1200\/JCO.19.02318","volume":"38","author":"S Modi","year":"2020","unstructured":"Modi S, Park H, Murthy RK, Iwata H, Tamura K, Tsurutani J, et al. Antitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib study. J Clin Oncol Off J Am Soc Clin Oncol. 2020;38:1887\u201396.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"1989_CR66","doi-asserted-by":"publisher","first-page":"3414","DOI":"10.1002\/ijc.32408","volume":"145","author":"N Takegawa","year":"2019","unstructured":"Takegawa N, Tsurutani J, Kawakami H, Yonesaka K, Kato R, Haratani K, et al. [fam-] trastuzumab deruxtecan, antitumor activity is dependent on HER2 expression level rather than on HER2 amplification. Int J Cancer. 2019;145:3414\u201324.","journal-title":"Int J Cancer"},{"key":"1989_CR67","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12957-024-03382-w","volume":"22","author":"L-Y Xia","year":"2024","unstructured":"Xia L-Y, Cao X-C, Yu Y. Survival outcomes in HER2-low versus HER2-zero breast cancer after neoadjuvant chemotherapy: a meta-analysis. World J Surg Oncol. 2024;22:106.","journal-title":"World J Surg Oncol"},{"key":"1989_CR68","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.clbc.2024.05.001","volume":"24","author":"M Liu","year":"2024","unstructured":"Liu M, Xiang Q, Dai F, Yuan Y, Wu Z, Xiang T. Comparison of the pathological complete response rate and survival between HER2-low and HER2-Zero breast cancer in neoadjuvant chemotherapy setting: a systematic review and meta-analysis. Clin Breast Cancer. 2024;24:575-584.e1.","journal-title":"Clin Breast Cancer"},{"key":"1989_CR69","doi-asserted-by":"publisher","first-page":"605","DOI":"10.2147\/BCTT.S366122","volume":"15","author":"Y Shirman","year":"2023","unstructured":"Shirman Y, Lubovsky S, Shai A. HER2-low breast cancer: current landscape and future prospects. Breast Cancer Targets Ther. 2023;15:605\u201316.","journal-title":"Breast Cancer Targets Ther"},{"key":"1989_CR70","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/s41379-022-01019-5","volume":"35","author":"H Zhang","year":"2022","unstructured":"Zhang H, Katerji H, Turner BM, Audeh W, Hicks DG. HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles. Mod Pathol. 2022;35:1075\u201382.","journal-title":"Mod Pathol"},{"key":"1989_CR71","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1093\/ajcp\/aqw045","volume":"145","author":"XB Li","year":"2016","unstructured":"Li XB, Krishnamurti U, Bhattarai S, Klimov S, Reid MD, O\u2019Regan R, et al. Biomarkers predicting pathologic complete response to neoadjuvant chemotherapy in breast cancer. Am J Clin Pathol. 2016;145:871\u20138.","journal-title":"Am J Clin Pathol"},{"key":"1989_CR72","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s10549-018-4801-3","volume":"170","author":"W Haque","year":"2018","unstructured":"Haque W, Verma V, Hatch S, Suzanne Klimberg V, Brian Butler E, Teh BS. Response rates and pathologic complete response by breast cancer molecular subtype following neoadjuvant chemotherapy. Breast Cancer Res Treat. 2018;170:559\u201367.","journal-title":"Breast Cancer Res Treat"},{"key":"1989_CR73","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1002\/cam4.5207","volume":"12","author":"M Han","year":"2023","unstructured":"Han M, Li J, Wu S, Wu C, Yu Y, Liu Y. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy. Cancer Med. 2023;12:2906\u201317.","journal-title":"Cancer Med"},{"key":"1989_CR74","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.soc.2017.08.004","volume":"27","author":"LN Chaudhary","year":"2018","unstructured":"Chaudhary LN, Wilkinson KH, Kong A. Triple-negative breast cancer: who should receive neoadjuvant chemotherapy? Surg Oncol Clin N Am. 2018;27:141\u201353.","journal-title":"Surg Oncol Clin N Am"},{"key":"1989_CR75","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.ctrv.2011.01.002","volume":"37","author":"SA Hurvitz","year":"2011","unstructured":"Hurvitz SA. Evolving options for the treatment of metastatic breast cancer: progression-free survival as an endpoint. Cancer Treat Rev. 2011;37:495\u2013504.","journal-title":"Cancer Treat Rev"},{"key":"1989_CR76","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.cct.2018.06.016","volume":"71","author":"V Nekljudova","year":"2018","unstructured":"Nekljudova V, Loibl S, von Minckwitz G, Schneeweiss A, Gl\u00fcck S, Crane R, et al. Trial-level prediction of long-term outcome based on pathologic complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC). Contemp Clin Trials. 2018;71:194\u20138.","journal-title":"Contemp Clin Trials"},{"key":"1989_CR77","doi-asserted-by":"crossref","unstructured":"de Moraes FCA, Souza MEC, Sano VKT, Moraes RA, Melo AC. Association of tumor-infiltrating lymphocytes with clinical outcomes in patients with triple-negative breast cancer receiving neoadjuvant chemotherapy: a systematic review and meta-analysis. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2024.","DOI":"10.1007\/s12094-024-03661-8"},{"key":"1989_CR78","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41523-023-00607-1","volume":"10","author":"E Zaikova","year":"2024","unstructured":"Zaikova E, Cheng BYC, Cerda V, Kong E, Lai D, Lum A, et al. Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment. NPJ Breast Cancer. 2024;10:3.","journal-title":"NPJ Breast Cancer"},{"key":"1989_CR79","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","volume":"391","author":"A Bardia","year":"2024","unstructured":"Bardia A, Hu X, Dent R, Yonemori K, Barrios CH, O\u2019Shaughnessy JA, et al. Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med. 2024;391:2110\u201322.","journal-title":"N Engl J Med"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-01989-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-025-01989-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-025-01989-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T16:45:03Z","timestamp":1742057103000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-025-01989-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1989"],"URL":"https:\/\/doi.org\/10.1186\/s13058-025-01989-9","relation":{},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"27 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39"}}